Skip to main content
. 2023 Aug 21;29(31):4706–4735. doi: 10.3748/wjg.v29.i31.4706

Table 4.

Efficacy of microRNAs combined with other biomarkers used in diagnosing hepatitis B virus-associated hepatocellular carcinoma

Comparison
miRNA
AUC
Sensitivity
Specificity
Ref.
HC miR-125b + miR-27a + AFP1 0.937 0.909 0.933 [30]
HC miR-125b + miR-223 + miR-27a + miR-26a + AFP 0.945 0.910 0.933 [30]
HC miR-125b + miR-223 + miR-27a + miR-26a + AFP2 0.972 0.944 0.900 [30]
HC miR-125b + miR-223 + miR-27a + miR-26a + AFP1 0.936 0.907 0.933 [30]
HC miR-125b + miR-223 + miR-27a + miR-26a + AFP1,2 0.956 0.800 1.000 [30]
HBV-carriers miR-20a-5p + miR-320a + miR-324-3p + miR-375 + AFP 0.789 0.700 0.775 [231]
HBV-carriers miR-20a-5p + miR-320a + miR-324-3p + miR-375 + AFP 0.767 0.640 0.838 [231]
CHB miR-96 + AFP 0.889 0.836 0.824 [34]
CHB miR-126 + AFP 0.920 0.840 0.920 [32]
CHB miR-142-3p + AFP 0.910 0.860 0.940 [32]
CHB miR-224 + AFP 0.867 0.875 0.765 [11]
CHB miR-125b + miR-27a + AFP1 0.722 0.600 0.833 [30]
CHB miR-125b + miR-223 + miR-27a + miR-26a + AFP 0.790 0.689 0.867 [30]
CHB miR-125b + miR-223 + miR-27a + miR-26a + AFP2 0.833 0.820 0.767 [30]
CHB miR-125b + miR-223 + miR-27a + miR-26a + AFP1 0.728 0.582 0.867 [30]
CHB miR-125b + miR-223 + miR-27a + miR-26a + AFP1,2 0.812 0.704 0.833 [30]
CHB miR-126 + miR-142-3p + AFP 0.930 0.880 0.970 [32]
HBV-DN let-7b + AFP 0.706 0.508 0.767 [233]
HBV-DN miR-122 + AFP 0.714 0.792 0.533 [233]
HBV-LC miR-99a + AFP 0.780 0.719 0.828 [232]
HBV-LC miR-101 + AFP 0.973 0.966 0.879 [24]
HBV-LC miR-122 + AFP + PIVKA-II 0.918 0.910 0.880 [37]
HBV-LC miR-126 + AFP 0.897 0.800 0.790 [32]
HBV-LC miR-142-3p + AFP 0.899 0.850 1.000 [32]
HBV-LC miR-205 + AFP 0.893 0.750 0.860 [36]
HBV-LC miR-224 + AFP 0.844 0.969 0.641 [11]
HBV-LC miR-126 + miR-142-3p + AFP 0.939 0.850 0.840 [32]
CHB + HBV-LC miR-224 + AFP 0.857 0.875 0.722 [11]
1

Comparing early-stage hepatitis B virus-associated hepatocellular carcinoma patients to patients with other stages.

2

Adjusting for gender and age differences.

HC: Healthy control; CHB: Chronic hepatitis B patient; HBV: Hepatitis B virus; HBV-DN: Hepatitis B virus-related dysplastic nodule patient; HBV-LC: Hepatitis B virus-related liver cirrhosis patient; AFP: Alpha fetoprotein; PIVKA-II: Prothrombin induced by vitamin K deficiency or antagonist- II; AUC: Area under the receiver operating characteristic curve; miRNAs: MicroRNAs.